文献速递鼻科

贝伐珠单抗联合氰基丙烯酸酯胶注射治疗遗传性出血性毛细血管扩张症

Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
PubMed 文献 · Laryngoscope · 2019-02-27

结果显示ESS评分从7.82显著降至3.89(P < .05),Bergler-Sadick评分及生活质量均显著改善,患者满意度高(平均7.03/10),无并发症。

要点

  • 贝伐珠单抗联合氰基丙烯酸酯胶可显著降低HHT患者鼻出血严重程度。
  • 该联合治疗改善患者生活质量和满意度,且未报告并发症。
  • 需前瞻性对照研究进一步验证该治疗模式的意义。

核心结论

  • 鼻内贝伐珠单抗联合氰基丙烯酸酯胶硬化治疗可显著减少HHT患者鼻出血并改善生活质量。

主要发现

  • 平均ESS评分从7.82显著降至3.89(P < .05)。
  • Bergler-Sadick评分显著改善(P < .05),其中频率从2.74降至1.64,数量从2.54降至1.51。
  • CL评分从4.16显著升至7.22(P < .05)。
  • Likert满意度量表平均7.03分(满分10分)。
  • 未报告并发症。

关键数值与推荐

  • 在毛细血管扩张基底部注射100 mg(25 mg/mL)贝伐珠单抗(稀释于2 mL血清中),并辅助使用氰基丙烯酸酯胶注射硬化治疗。
  • 疗效评估基于ESS评分和Bergler-Sadick量表变化,生活质量采用Cantril自锚阶梯(CL)评估,满意度采用Likert量表。

临床怎么用

  • 对于HHT难治性鼻出血,可考虑鼻内贝伐珠单抗联合氰基丙烯酸酯胶硬化治疗以降低出血严重程度并改善生活质量。

局限性

  • 回顾性研究设计,证据等级为3b。
  • 需前瞻性对照研究进一步评估该治疗模式的意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: The objective of this study was to report for the first time on the results of submucosal injections of bevacizumab used in conjunction with cyanoacrylate glue sclerotherapy in hereditary hemorrhagic telangiectasia (HHT). STUDY DESIGN: Retrospective analytic chart review. METHODS: We performed a chart review that included all patients with HHT treated with intranasal bevacizumab and cyanoacrylate glue for refractory epistaxis at Lariboisiere University Hospital from 2013 with a minimum follow-up of 6 months. We injected 100 mg (25 mg/mL) of bevacizumab diluted in 2 mL of serum at the base of the telangiectasias, and sclerotherapy with an injection of cyanoacrylate glue was used adjunctively. Treatment efficacy was based on changes in Epistaxis Severity Scores (ESS) and the Bergler-Sadick Scale. Quality of life and patient satisfaction were evaluated using the Cantril Self-Anchoring Ladder (CL) and Likert scale, respectively. RESULTS: Thirty-one patients were included, with a mean follow-up of 26.6 months. The average ESS score significantly decreased from 7.82 to 3.89 (P < .05). The Bergler-Sadick score significantly improved (P < .05) following the treatment, including the frequency (from 2.74 to 1.64) and the quantity (from 2.54 to 1.51) scales. Quality of life was significantly improved (P < .05) using the CL score (from 4.16 to 7.22). The Likert satisfaction scale related to the treatment efficacy was high, with an average of 7.03 out of 10. No complications were noted. CONCLUSIONS: Submucosal injections of bevacizumab in conjunction with cyanoacrylate glue sclerotherapy significantly reduced epistaxis and improved the quality of life in HHT. Prospective comparative studies are needed to further evaluate the significance of this treatment modality. LEVEL OF EVIDENCE: 3b Laryngoscope, 129:2210-2215, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Khoueir N, Borsik M, Camous D, et al. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia. Laryngoscope. 2019. PMID: 31566760. doi:10.1002/lary.27889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。